Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases

Proceedings of the Society for Experimental Biology and Medicine

Volumn 215, Issue 1, 1997, Pages 11-20

  Umetsu, Dale T ^a   Dekruyff, Rosemarie H ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E;

ALLERGIC DISEASE; BASOPHIL; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MAST CELL; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION;

EID: 0030945106     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-215-44109     Document Type: Short Survey

References (72)

1. Lukacs NW, Strieter RM, Kunkel SL. Leukocyte infiltration in allergic airway inflammation. Am J Respir Cell Mol Biol 13:1-6, 1995.
2. Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D. Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 154:1870-1878, 1995.
3. Pattison JM, Nelson PJ, Krensky AM. The RANTES chemokine. A new target for immunomodulatory therapy? Clin Immunother 4:1-8, 1995.
4. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. J Aller Clin Immunol 94:427-438, 1994.
5. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304, 1992.
6. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone: Implications for immune regulation. Immunol Today 8:223-226, 1987.
7. Umetsu DT, Jabara HH, DeKruyff RH, Abbas AK, Abrams JS, Geha RS. Functional heterogeneity among human inducer T cell clones. J Immunol 140:4211-4216, 1988.
8. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 76:241-251, 1994.
9. Parish CR, Liew FY. Immune response to chemically modified flagellin. III. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med 135:298, 1972.
10. Kamogawa Y, Minasi LE, Carding SR, Bottomly K, Flavell RA. The relationship of IL-4- and IFN-γ-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75:985-995, 1993.
11. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227-257, 1994.
12. - helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon. J Exp Med 174:547-559, 1991.
13. + T cells requires repeated antigenic stimulation. Cell Immunol 152:18-34, 1993.
14. Swain SL. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity 1:543-552, 1994.
15. + T cells. J Clin Immunol 15:105-115, 1995.
16. + T cells producing Th2-type cytokines. FASEB J 9:81-86, 1995.
17. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265:1237-1240, 1994.
18. + beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 182:87-97, 1995.
19. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-282, 1991.
20. Gajewski TF, Qian D, Fields P, Fitch FW. Anergic T-lymhocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci 91:38-42, 1994.
21. Gajewski TF, Lancki DW, Stack R, Fitch FW. "Anergy"of Th0 helper T lymphocytes induces downregulation of Th1 characteristics and a transition to a Th2-like phenotype. J Exp Med 179:481-491, 1994.
22. Weiner HL, Friedman A, Miller A, Khoury SJ, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12:809-837, 1994.
23. Scott B, Liblau R, Degermann S, Marconi L, Ogata L, Caton A, McDevitt H, Lo D. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1:73, 1994.
24. Oro AS, Guarino TJ, Driver R, Steinman L, Umetsu DT. Regulation of disease susceptibility: Decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. J Aller Clin Immunol 97:1402-1408, 1996.
25. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 181:1569-1574, 1995.
26. + T cells. J Exp Med 182:1591-1596, 1995.
27. Shirakawa T, Li A, Dubowitz M, Dekker JW, Shaw AE, Faux JA, Ra C, Cookson WO, Hopkin JM. Association between atopy and variants of the β subunit of the high-affinity immunoglobulin E receptor. Nat Genet 7:125-130, 1994.
28. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 264:1152-1156, 1994.
29. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Schou C, Beaty TH. Genetic basis of IgE responsiveness: Relevance to the atopic diseases. Intern Arch Aller Immunol 107:25-28, 1995.
30. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320:271, 1989.
31. Shanker AH, Titus RG. T cell and non-T cell compartments can independently determine resistance to Leishmania major. J Exp Med 181:845-855, 1995.
32. Hsieh C-S, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 181:713-721, 1995.
33. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276, 1995.
34. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 2:665-675, 1995.
35. Pernis A, Gupta S, Gollob KJ, Garfein E, Coffman RL, Schindler C, Rothman P. Lack of interferon γ receptor β chain and the prevention of interferon γ signaling in Th1 cells. Science 269:245-247, 1995.
36. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL. Overexpression of IL-10 in atopic dermatis. Contrasting cytokine patterns with delayed type hypersensitivity reactions. J Immunol 154:1956-1963, 1995.
37. Gieni RS, Fang Y, Trinchieri G, Umetsu DT, DeKruyff RH. Differential production of IL-12 in distinct mouse strains controls the development of Th1 versus Th2 cytokine profiles in primed CD4 lymphocytes. Int Immunol 8:1511-1520, 1996.
38. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6:414, 1994.
39. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80:707-718, 1995.
40. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke X, Rennert P, Gray GS, Gridden JG, Nadler LM. B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523-532, 1995.
41. Lenshow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145-1155, 1995.
42. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465, 1995.
43. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multi-organ tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547, 1995.
44. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr., Ke X, Gray GS, Nadler LM. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci 92:811-815, 1995.
45. Lu P, Zhou XD, Chen SJ, Moorman M, Schoneveld A, Morris S, Finkelman FD, Linsley P, Claassen E, Gause WC. Requirement of CTLA-4 counter receptors for IL-4 but not IL-10 elevations during a primary systemic in vivo immune response. J Immunol 154:1078-1087, 1995.
46. + T cells. Immunol Today 12:392-395, 1991.
47. Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HCI, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 and IL-10. J Virol 68:5321-5325, 1994.
48. Tang Y-W, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 94:1953-1958, 1994.
49. + T-cell subsets in vivo. Immunol Rev 123:189-207, 1991.
50. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J Exp Med 182:1579-1584, 1995.
51. Holt PG. Immunoprophylaxis of atopy: Light at the end of the tunnel? Immunol Today 15:484-489, 1994.
52. + cells from allergic individuals is modulated by allergen concentration and antigen-presenting cell type. J Exp Med 181:1081-1090, 1995.
53. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92:644-651, 1993.
54. + T cells from allergic individuals. J Exp Med 178:2123-2130, 1993.
55. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154:4187-4194, 1995.
56. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177:1797-1802, 1993.
57. + T cells. Science 263:235, 1994.
58. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci 92:3142-3146, 1995.
59. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper Type 1 cells and accelerates autoimune diabetes in NOD mice. J Exp Med 181:817-821, 1995.
60. Leonard JP. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 181:381-386, 1995.
61. Gavett SH, O'Hearn DJ, Li X, Huang S-K, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 182:1527-1536, 1995.
62. + T lymphocytes. J Immunol 155:111-117, 1995.
63. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, O'Garra A. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 183:901-913, 1996.
64. + T cells through an effect on antigen-presenting cells. J Immunol 154:2578-2587, 1995.
65. Finkelman FD, Madden KB, Cheever AW, Katona IM, Morris SC, Gately MK, Hubbard BR, Gause WC, Urban JF Jr. Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 179:1563-1572, 1994.
66. Bliss J, Van CV, Murray K, Wiencis A, Ketchum M, Maylor R, Haire T, Resmini C, Abbas AK, Wolf SF. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 156:887-894, 1996.
67. Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, Hsieh KH. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Medicine 2:540-544, 1996.
68. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354, 1996.
69. Wallner BP, Gefter ML. Immunotherapy with T cell reactive peptides derived from allergens. Allergy 49:302-308, 1994.
70. Critchfield JM, Racke M, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139-1143, 1994.
71. Briner TJ, Kuo M-C, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci 90:7608-7612, 1993.
72. Norman PS, Ohman MD, Long AA, Creticos PS, Gefter ML, Shaked Z, Wood RA, Eggleston PA, Lichtenstein LM, Jones NH, Nicodemus CF. Follow on study of the first clinical trial with T cell defined peptides from cat allergen Fel d 1. J Aller Clin Immunol 95:A259, 1995.